Physician profile
Lean A Sterry
NPI 1508139452
$2,034.83
in general payments reported to CMS, 2019-2025
31 companies · $282 in 2025
The $282 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $164 · 2021: $252 · 2022: $277 · 2023: $266 · 2024: $466 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $247.17 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $176.44 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $132.17 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.21 | 2020-2024 | Eohilia |
| Glaxosmithkline, LLC. | $124.50 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Sanofi Pasteur INC. | $108.55 | 2023-2024 | |
| Tris Pharma INC | $99.94 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Verrica Pharmaceuticals INC. | $97.33 | 2024-2025 | Ycanth |
| Ironshore Pharmaceuticals INC. | $85.07 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $81.98 | 2019-2024 | Auvi-Q |
| Exeltis, USA INC. | $77.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.57 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $65.60 | 2023-2024 | Koselugo |
| Seqirus USA INC | $58.87 | 2022-2024 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $53.89 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $51.12 | 2022-2023 | Azstarys |
| Sobi, INC | $46.91 | 2019-2023 | |
| Adlon Therapeutics L.P. | $44.70 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2021 | |
| Genentech USA, INC. | $40.98 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $37.74 | 2025 | Jornay Pm |
| Ars Pharmaceuticals Operations, INC. | $25.15 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $19.22 | 2024 | Qelbree |
| Ironwood Pharmaceuticals, INC | $18.83 | 2024 | |
| Meridian Bioscience INC. | $18.80 | 2019 | |
| Shire North American Group INC | $16.44 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.36 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.69 | 2019 | |
| Phadia US INC. | $14.49 | 2025 | Immunocap |
| Mission Pharmacal Company | $12.67 | 2019 | |
| Neos Therapeutics, LP | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lean Sterry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.